Association Between Helicobacter Pylori Infection and Long-term Outcome in Patients with Drug-eluting Stent Implantation

Abstract

To investigate the relationship between Helicobacter pylori (Hp) infection and the long-term outcome in acute coronary syndrome (ACS) patients with drug-eluting stent (DES) implantation and so as to explore the significance of Hp eradication therapy in preventing major adverse cardiac events (MACE) and upper gastrointestinal bleeding (UGIB). 539 ACS patients with DES implantation from January 1, 2010 to December 31, 2012 were analyzed. All the patients were divided into two groups according to the result of 13C urea breath test. 253 patients with Hp infection were put into group A (Hp+), and 286 cases without Hp infection were put into group B (Hp−). Demographic data was collected and all patients went through biochemical indicators and other routine blood examinations. We explored the correlations of Hp infection with MACE and UGIB after 3 to 5 years of follow-up using survival analysis. Survival analysis showed that Hp infection was a predictor of MACE and UGI. Sub-group analysis showed that patients with Hp eradication therapy had no relationship with MACE but had a lower rate of UGIB than those without Hp eradication therapy.

Helicobacter pylori infection and risk of cardiovascular disease

“…Thirty‐nine studies were included for the comparisons between H. pylori infection and non‐ H. pylori infection, while two studies 34,35 included all patients with H. pylori infection and provided data to evaluate the risk of CVD between patients with different CagA expressions. Of the included studies, 30 of them were from the general population, 17,21,35–62 9 were from patients with established CVD, 19,22,34,63–68 and 2 were from patients with other chronic diseases 69,70 (1 included hemodialysis patients, 1 included patients with type 2 diabetes). The baseline characteristics of the included studies were presented in Table S2.…”

“…After screening the titles and abstracts, 180 full‐length articles were reviewed, and 41 studies were finally included for analysis (Figure 1). 17,19,21,22,34–70 Totally, there were 230,288 participants, with a median follow‐up duration of 6.3 years in the included studies. Thirty‐nine studies were included for the comparisons between H. pylori infection and non‐ H. pylori infection, while two studies 34,35 included all patients with H. pylori infection and provided data to evaluate the risk of CVD between patients with different CagA expressions.…”